Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
- PMID: 32217611
- DOI: 10.1158/1078-0432.CCR-20-0097
Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
Abstract
Matched pre-/posttreatment tissue biopsies from patients with EGFR-mutant non-small cell lung cancer demonstrate that histologic transformations, including both small-cell carcinoma and squamous transformation, are unexpectedly common among patients progressing on first-line osimertinib. The study highlights the key role of tissue testing and underscores the need for innovative therapeutic approaches to prevent, rather than treat, resistance.See related article by Schoenfeld et al., p. 2654.
©2020 American Association for Cancer Research.
Comment in
-
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.Clin Cancer Res. 2020 Jun 1;26(11):2654-2663. doi: 10.1158/1078-0432.CCR-19-3563. Epub 2020 Jan 7. Clin Cancer Res. 2020. PMID: 31911548 Free PMC article.
Comment on
-
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.Clin Cancer Res. 2020 Jun 1;26(11):2654-2663. doi: 10.1158/1078-0432.CCR-19-3563. Epub 2020 Jan 7. Clin Cancer Res. 2020. PMID: 31911548 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous